```html

Idiopathic Thrombocytopenic Purpura (ITP): A Comprehensive Patient Guide

Overview

Idiopathic thrombocytopenic purpura (ITP), also called immune thrombocytopenia, is an autoimmune disorder in which the body’s immune system mistakenly attacks and destroys platelets – the tiny blood‑cell fragments that help clot bleeding. The result is a low platelet count (thrombocytopenia) that can cause easy bruising, bleeding, and, in severe cases, life‑threatening hemorrhage.

Who it affects: ITP can occur at any age, but it shows a biphasic pattern. Children (especially between 2‑5 years) often develop acute ITP after a viral infection and usually recover within 6‑12 months. Adults—particularly women aged 20‑40—are more likely to develop the chronic form, which may persist for years. Approximately 3‑4 per 100,000 people in the United States are diagnosed each year, with women accounting for about 60 % of adult cases (CDC, 2023)【1】.

**Prevalence**: The overall prevalence of chronic ITP in adults is estimated at 9.5 per 100,000 people, rising to 23 per 100,000 in those > 60 years old. Pediatric acute ITP affects roughly 5–8 per 100,000 children annually【2】.

Symptoms

Symptoms result from low platelet numbers; they vary from mild to severe.

• Bruising (purpura) – pink‑to‑purple spots, often on the arms or legs.
• Petechiae – tiny red or purple dots that look like a rash, especially on the lower legs, mouth, or under the eyes.
• Epistaxis – frequent or prolonged nosebleeds.
• Bleeding gums – spontaneous bleeding after brushing or flossing.
• Heavy menstrual bleeding (menorrhagia) – common in women of reproductive age.
• Hematuria – blood in the urine.
• Hemoptysis – coughing up blood (rare).
• Gastrointestinal bleeding – black, tarry stools (melena) or bright red blood.
• Prolonged bleeding after cuts, dental work, or surgery.
• Fatigue – often related to anemia from chronic blood loss.
• Headache or neurological symptoms – very low platelets (< 10 × 10⁹/L) can cause intracranial hemorrhage, presenting as severe headache, confusion, or loss of consciousness.

Causes and Risk Factors

Underlying Mechanism

ITP is classified as “idiopathic” because the exact trigger is unknown in many cases. The prevailing theory is that auto‑antibodies (mostly IgG) bind to platelet surface proteins, marking them for destruction by the spleen and liver. In addition, impaired platelet production in the bone marrow contributes to the low count.

Identified Triggers

• Infections – especially viral (e.g., Epstein‑Barr virus, cytomegalovirus, hepatitis C, HIV). In children, a recent viral upper‑respiratory infection often precedes acute ITP.
• Vaccinations – rare cases have been reported after MMR, influenza, and COVID‑19 vaccines; causality is not established but temporal association exists.
• Medications – drug‑induced ITP can occur with quinine, sulfonamides, certain antibiotics, and heparin (heparin‑induced thrombocytopenia is a distinct entity).
• Other autoimmune diseases – lupus, rheumatoid arthritis, and autoimmune thyroid disease increase risk.

Risk Factors

• Female sex (especially ages 20‑40)
• History of autoimmune disease
• Recent viral infection or vaccination
• Certain medications or herbal supplements (e.g., quinine)
• Genetic predisposition – family clustering is rare but suggested in some studies.

Diagnosis

Diagnosing ITP is a process of exclusion; other causes of low platelets must be ruled out.

Clinical Evaluation

• Detailed medical history (bleeding symptoms, infections, drug exposure, family history).
• Physical exam focusing on bruises, petechiae, mucosal bleeding, and splenomegaly.

Laboratory Tests

1. Complete Blood Count (CBC) – shows isolated thrombocytopenia; hemoglobin and white cells typically normal.
2. Peripheral Blood Smear – evaluates platelet size (often larger) and rules out abnormal cells suggestive of leukemia.
3. Coagulation profile (PT/INR, aPTT) – usually normal, helping exclude coagulation disorders.
4. Serologic tests – hepatitis C, HIV, and Helicobacter pylori screening when risk factors exist.
5. Autoimmune panel – ANA, anti‑dsDNA if systemic lupus is suspected.

When to Perform Bone Marrow Examination

Recommended if platelet count < 10 × 10⁹/L, atypical features (e.g., blasts on smear), or if the patient does not respond to first‑line therapy. The procedure is safe and provides definitive information about marrow production.

Diagnostic Criteria (Adult Chronic ITP)

• Platelet count < 100 × 10⁹/L on at least two separate occasions ≥ 1 month apart
• No evidence of another cause (infection, drug, systemic disease)
• Exclusion of marrow failure syndromes via smear or biopsy if indicated

Treatment Options

Treatment is individualized based on platelet count, bleeding severity, age, comorbidities, and patient preference. Not every patient requires immediate therapy; many adults with platelet counts > 30 × 10⁹/L and no bleeding are observed.

First‑Line Therapies

• Corticosteroids – Prednisone 1 mg/kg/day (max 80 mg) for 4‑6 weeks, then taper. Works by reducing antibody production.
• Intravenous immunoglobulin (IVIG) – 1 g/kg daily for 1‑2 days; useful for rapid platelet rise in severe bleeding or before surgery.
• Anti‑D immunoglobulin (Rho(D) immune globulin) – for Rh‑positive, non‑splenectomized patients; dose 50‑75 µg/kg.

Second‑Line / Chronic Management

• Thrombopoietin receptor agonists (TPO‑RAs) – Eltrombopag (Revolade) or Romiplostim (Nplate). They stimulate platelet production and have become first‑line for many adults with chronic ITP.
• Rituximab – Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks. Useful when steroids fail and patient prefers to avoid splenectomy.
• Splenectomy – Surgical removal of the spleen; historically the most effective durable treatment (remission in 60‑70 % of cases). Considered after ≥ 12 months of refractory disease.
• Immunosuppressants – Mycophenolate mofetil, azathioprine, or cyclophosphamide in select refractory cases.

Supportive Care & Lifestyle Measures

• Avoid NSAIDs, aspirin, and other antiplatelet agents unless specifically prescribed.
• Use soft toothbrushes; avoid floss that may cause gum trauma.
• Apply gentle pressure to minor cuts; keep nails trimmed to prevent skin tears.
• Vaccinate against encapsulated organisms (pneumococcus, meningococcus, Haemophilus) if the spleen is removed or functional hyposplenia is present.

Pregnancy Considerations

ITP can worsen, improve, or remain stable during pregnancy. Low‑dose steroids or IVIG are first‑line because they have the best safety profile for mother and fetus. Close obstetric and hematology collaboration is essential.

Living with Idiopathic Thrombocytopenic Purpura

Monitoring

• Regular CBC checks: every 1‑3 months if stable; more often when starting or changing therapy.
• Track bleeding episodes in a diary; note triggers such as vigorous exercise or new medications.

Daily Activity Tips

• Prefer low‑impact sports (swimming, walking, stationary cycling) over contact sports.
• Wear protective padding when falling is possible (e.g., knee pads).
• Use electric razors instead of blade razors to reduce skin cuts.
• Stay hydrated and maintain a balanced diet rich in iron, vitamin C, and folate to support overall blood health.

Emotional & Social Support

Chronic ITP can cause anxiety about bleeding. Joining patient groups (e.g., ITP International Foundation) and speaking with a mental‑health professional can improve coping. Explain the condition to close friends and coworkers; carrying a “medical alert” card is advisable.

Prevention

Because ITP is largely idiopathic, primary prevention is limited. However, risk can be reduced by:

• Avoiding unnecessary medication use, especially quinine‑containing products and over‑the‑counter NSAIDs without physician guidance.
• Promptly treating infections and discussing vaccination risks with a healthcare provider; most vaccines are safe and the benefits outweigh the rare risk of ITP.
• Screening and treating H. pylori infection, which has been linked to persistent thrombocytopenia in some adults.

Complications

If left untreated or poorly controlled, ITP can lead to serious outcomes:

• Severe bleeding – intracranial hemorrhage (most feared), gastrointestinal bleed, or retro‑orbital hemorrhage.
• Fatigue and anemia due to chronic blood loss.
• Side‑effects from long‑term steroids – osteoporosis, hyperglycemia, hypertension, cataracts, mood changes.
• Infection risk after splenectomy – overwhelming postsplenectomy infection (OPSI); requires lifelong vaccines and prophylactic antibiotics in some cases.
• Medication‑related toxicities – liver dysfunction with eltrombopag, thromboembolic events with some TPO‑RAs, infusion reactions with rituximab.

When to Seek Emergency Care

---

References:
1. Centers for Disease Control and Prevention. “Immune Thrombocytopenic Purpura (ITP).” 2023. https://www.cdc.gov/ithp.
2. Rodeghiero, F., et al. “Epidemiology of Immune Thrombocytopenia.” *Blood*, vol. 129, no. 11, 2017, pp. 1470‑1477.
3. Cines, D. B., & Blanchette, V. S. “Immune Thrombocytopenic Purpura.” *The New England Journal of Medicine*, 2020;382: 2043‑2054.
4. Mayo Clinic. “Immune thrombocytopenic purpura (ITP) – Symptoms and causes.” 2024. https://www.mayoclinic.org.
5. National Institute of Allergy and Infectious Diseases. “Immune Thrombocytopenia (ITP).” 2022. https://www.niaid.nih.gov.
6. World Health Organization. “Guidelines for the Management of ITP.” 2021.

```